EVA-RA Project

• Research type

  Research Study

• Full title

  Exploring the Variation in Care and Access to High-Cost Drugs for the Treatment of Rheumatoid Arthritis – ‘EVA-RA’

• IRAS ID

  281162

• Contact name

  David Walker

• Contact email

  david.walker@nhct.nhs.uk

• Sponsor organisation

  Northumbria Healthcare NHS Foundation Trust

• Duration of Study in the UK

  1 years, 6 months, 1 days

• Research summary

  The National Institute of Clinical Excellence (NICE) provide guidelines on the management of patients with Rheumatoid Arthritis (RA). These guidelines specify that a high disease activity score (DAS) over 5.1 is required in order to prescribe certain high cost drugs. NICE do not limit the number of drugs which can be used to manage difficult to treat Rheumatoid Arthritis. However, a number of Clinical Commissioning Groups,(CCGs) do limit the number of high cost drugs which can be used, which could have an impact on patient care. We would like to determine how many CCGs are implementing limitations, what they are and how this impacts on the patient and management powers of the care providers.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  20/LO/0822

• Date of REC Opinion

  30 Jul 2020

• REC opinion

  Favourable Opinion